Hubei FDA To Inspect Production Of National Essential Drugs
This article was originally published in PharmAsia News
Hubei FDA recently announced it will launch an inspection of the province's national essential drug production in November and December, aiming to fully understand the regulatory work that ensures safe drug consumption
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.